Biogen Inc.
NASDAQBIIB reported Q2 results this morning with an unusual setup: options traders turned sharply more defensive just as short sellers were quietly adding to positions — a tension worth unpacking given the stock's modest 1.2% gain on the week. The clearest signal came from options. The put/call ratio jumped to 0.83 on Tuesday — nearly three standard deviations above its 20-day average of…
Snapshot as of 26 Aug 2026
BIIB reported Q2 results this morning with an unusual setup: options traders turned sharply more defensive just as short sellers were quietly adding to positions — a tension worth unpacking given the stock's modest…
BIIB heads into its July 29 earnings date swimming against the biotech tide — down nearly 5% on the week while close peers REGN and IONS each rallied more than 7% over the same period. The divergence is notable. Where…
BIIB heads into its June 9 earnings print with a notable upgrade landing just hours before the bell, creating a sharp contrast with a defensive options tape and a short book that has grown steadily all month. The…
BIIB pulls back into its June 9 earnings print with the stock softer on the week and short sellers adding positions at a pace that has gone largely unnoticed — the quieter story beneath an otherwise bullish analyst…
BIIB enters its June 9 earnings event with a busier-than-usual week of Street activity — analysts raising targets, a securities fraud investigation making noise in the background, and a pipeline setback still fresh in…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for BIIB — free to start on ORTEX.
Sign up for free →Open BIIB on ORTEX